Cargando…
LBODP041 Effects Of Sodium-glucose Co-transporter 2 Inhibitors (sglt-2 Inhibitors) On Adipokines And Inflammatory Biomarkers In Type2 Diabetic Patients
BACKGROUND: Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. SGLT-2 inhibitors reduce HbA1c and show favorable effects on body weight, blood pressure, lipid profile, arterial stiffness, and endothelial function. More importantly, SGLT-2 inhibitor...
Autor principal: | Kumtree, Phonphruet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624710/ http://dx.doi.org/10.1210/jendso/bvac150.551 |
Ejemplares similares
-
LBODP062 SGLT2 Inhibition Ameliorates Cognitive And Physical Impairment In Patients With HFpEF And Diabetes
por: Mone, Pasquale, et al.
Publicado: (2022) -
Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients
por: Saleem, Muhammad, et al.
Publicado: (2021) -
THU291 Successful Reversal Of Glucose Toxicity After DKA Precipitated By SGLT2 Inhibitor
por: Abdelrahman, Houda, et al.
Publicado: (2023) -
LBODP046 Reduction In "Cardiovascular Death Or Hospitalisation For Heart Failure" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis
por: Ghosal, Samit, et al.
Publicado: (2022) -
ODP252 Urosepsis and Sodium-Glucose Co-Transporter-2 Inhibitors: A Systematic Review and Meta-Analysis
por: Prasongdee, Klaorat, et al.
Publicado: (2022)